glp-1 drugs market dynamics 2025 Receptor Agonist Valued at USD 62.86 Billion in 2025, Set to Grow at 17.5% CAGR Through 2034 GLP-1 Agonists Market Exclusive Research

However, the rate of endoscopic procedure interruption was higher in patients treated with GLP-1 RAs, possibly due to increased gastric contents

Its prevalence ranges between 5 and 21% 1 , depending on the diagnostic criteria, with higher frequency in women with obesity and specific ethnic groups 2,3

However, caution should be exercised in patients with a history of pancreatitis, and GLP-1 receptor agonist therapy should be discontinued if pancreatitis develops (613)

However, a significant increase in Bifidobacterium, Dialister , and Alistipes was reported (73)

In such cases, GLP-1 hormone can help contribute to glucose control by stimulating glucose-dependent insulin release, reducing glucagon secretion, slowing gastric emptying, and eventually enhancing satiety

But its always important to keep tracking the safety of every drug once it reaches the public